Search

Objective: Non-alcoholic fatty liver disease (NAFLD) is an established risk factor for diabetes, cardiovascular disease, antiviral treatment resistance, and progression of chronic hepatitis C virus (HCV) infection to fibrosis. Apolipoprotein-B 100 (ApoB-100) is a dyslipidemia marker and steatosis predictor. We assess the correlation between ApoB-100 and hepatosteatosis. Methods: This cross-sectional study enrolled 1,218 HCV-seropositive participants from a 2012-2013 health checkup in Taiwan. NAFLD was detected using ultrasound. All anthropometric and laboratory studies that included ApoB-100 were evaluated whether or not ApoB-100 predicts NAFLD. Logistic regression was also used to examine the association between ApoB-100 and NAFLD. Results: Participants were 47.16 ± 16.08 years old (mean age). The overall prevalence of NAFLD was 35.8% (n = 436; 32.8% men, 38.1% women). Participants with ApoB-100 ≥ 8 had a significantly higher incidence of NAFLD (39.4 vs. 29.4%; 95% CI 0.044-0.156; p Conclusion: ApoB-100 is strongly associated with NAFLD in people with non-genotype 3 HCV; greater ApoB-100 content is significantly correlated with higher-grade hepatosteatosis.

Abstract Alternative intravesical agents are required to overcome the side effects currently associated with the treatment of bladder cancer. This study used an orthotopic bladder cancer mouse model to evaluate Guizhi Fuling Wan (GFW) as an intravesical agent. The effects of GFW were compared with those of mitomycin-C (Mito-C) and bacille Calmette-Guérin (BCG). We began by evaluating the response of the mouse bladder cancer cell line MB49 to GFW treatment, with regard to cell viability, cell cycle progression and apoptosis. MB49 cells were subsequently implanted into the urothelial walls of the bladder in female C57BL/6 mice. The success of the model was confirmed by the appearance of hematuria and tumor growth in the bladder. Intravesical chemotherapy was administered in accordance with a published protocol. In vitro data revealed that GFW arrested MB49 cell cycle in the G0/G1 phase, resulting in the suppression of cell proliferation and induced apoptosis. One possible mechanism underlying these effects is an increase in intracellular reactive oxygen species (ROS) levels leading to the activation of ataxia telangiectasia-mutated (ATM)/checkpoint kinase 2 (CHK2) and ATM/P53 pathways, thereby mediating cell cycle progression and apoptosis, respectively. This mouse model demonstrates the effectiveness of GFW in the tumor growth, with results comparable to those achieved by using BCG and Mito-C. Furthermore, GFW was shown to cause only mild hematuria. The low toxicity of the compound was confirmed by a complete lack of lesions on bladder tissue, even after 10 consecutive treatments using high concentrations of GFW. These results demonstrate the potential of GFW for the intravesical therapy of bladder cancer.

As passive rehabilitation training with fixed trajectory ignores the active participation of patients, in order to increase the active participation of patients and improve the effect of rehabilitation training, this paper proposes an innovative adaptive sliding mode variable admittance (ASMVA) controller for the Lower Limb Rehabilitation Exoskeleton Robot. The ASMVA controller consists of an outer loop with variable admittance controller and an inner loop with an adaptive sliding mode controller. It estimates the wearer’s active muscle strength and movement intention by judging the deviation between the actual and standard interaction force of the wearer’s leg and the exoskeleton, thereby adaptively changing admittance controller parameters to alter training intensity. Three healthy volunteers engaged in further experimental studies, including trajectory tracking experiments with no admittance, fixed admittance, and variable admittance adjustment. The experimental results show that the proposed ASMVA control scheme has high control accuracy. Besides, the ASMVA can not only increase training intensity according to the active muscle strength of the patient during positive movement intention (so as to increase active participation of the patient), but also increase the amount of trajectory adjustment during negative movement intention to ensure the safety of the patient.

Objective: To describe the technique and outcomes of antegrade ureteroscopic assistance during the initial nephrostomy access for the management of renal staghorn stone. Materials and methods: From 2000 to 2009, a total of 153 patients with complete staghorn stones were treated with percutaneous nephrolithotomy (PCNL) at our hospital. Antegrade ureteroscopic assistance was applied, starting in the 50th patient, during the initial nephrostomy access so as to prevent the creation of a false tract and to create more intracalyceal space for subsequent tract dilation. We report the characteristics of the patients, stones, treatment outcomes, and complications in the groups with and without antegrade ureteroscopic assistance. Results: Intergroup differences in the groups with (n = 104) and without (n = 49) antegrade ureteroscopic assistance with regard to the patients' characteristics and stone surface areas were not significant (24.0 ± 18.1 cm2 versus 21.8 ± 11.8 cm2). Patients who underwent PCNL with antegrade ureteroscopic assistance required a significantly shorter operation time and hospital stay than those who underwent PCNL without antegrade ureteroscopic assistance (143 ± 78 minutes versus 105 ± 35 minutes, p